Literature DB >> 25240995

Peripheral giant cell granulomas: a series of 279 cases.

S Reid Lester1, Kitrina G Cordell2, Molly S Rosebush3, A Archontia Palaiologou4, Pooja Maney5.   

Abstract

OBJECTIVE: This study investigated the demographic, clinicopathologic, and histopathologic findings of lesions diagnosed as peripheral giant cell granuloma (PGCG) by the Louisiana State University Oral Pathology Biopsy Service from 1974 to 2011. STUDY
DESIGN: Clinical, demographic, and histopathologic evaluation was completed for 279 cases. A follow-up questionnaire was mailed to all surgeons who performed these biopsies from 1990 to 2011.
RESULTS: Of the 279 lesions, 58% occurred in the mandible, 44% occurred in the anterior portion of the arches, 83% were adjacent to teeth, 14% occurred in edentulous areas, and 2% were adjacent to implants. Average duration was 10.5 months, and the average size was 12.7 mm. The recurrence rate was 17.5%. Histopathologically, 78% of lesions extended to the base of the specimen, 50% exhibited ulceration, 41% contained calcifications, and 6% exhibited features overlapping with another pathologic entity.
CONCLUSIONS: PGCG is a well-defined pathologic entity among reactive gingival lesions. Recurrent lesions were more likely to contain calcifications.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25240995     DOI: 10.1016/j.oooo.2014.06.004

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol


  9 in total

Review 1.  Insight into the pathogenesis and nature of Central Giant Cell Lesions of the Jaws.

Authors:  Paul-Charles Edwards
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2015-03-01

Review 2.  Pyogenic Granuloma/Peripheral Giant-Cell Granuloma Associated with Implants.

Authors:  Enric Jané-Salas; Rui Albuquerque; Aura Font-Muñoz; Beatríz González-Navarro; Albert Estrugo Devesa; Jose López-López
Journal:  Int J Dent       Date:  2015-12-01

3.  Peripheral Giant Cell Granuloma in a Child Associated with Ectopic Eruption and Traumatic Habit with Control of Four Years.

Authors:  Luiz Evaristo Ricci Volpato; Cristhiane Almeida Leite; Brunna Haddad Anhesini; Jéssica Marques Gomes da Silva Aguilera; Álvaro Henrique Borges
Journal:  Case Rep Dent       Date:  2016-11-24

Review 4.  Lumps and Bumps of the Gingiva: A Pathological Miscellany.

Authors:  Daniel J Brierley; Hannah Crane; Keith D Hunter
Journal:  Head Neck Pathol       Date:  2019-01-29

5.  A rare low-grade myofibroblastic sarcoma in lower jaw with the resemblance to benign lesions.

Authors:  Martina C Schwerzmann; Matthias S Dettmer; Daniel Baumhoer; Tateyuki Iizuka; Valerie G A Suter
Journal:  BMC Oral Health       Date:  2022-09-05       Impact factor: 3.747

6.  Gingival Fibroma: An Emerging Distinct Gingival Lesion with Well-Defined Histopathology.

Authors:  M Bawazir; M N Islam; D M Cohen; S Fitzpatrick; I Bhattacharyya
Journal:  Head Neck Pathol       Date:  2021-03-08

7.  Peripheral giant cell granuloma recurring as an exclusively intra-osseous lesion: An unusual clinical presentation.

Authors:  Kedar Vaidya; Gargi S Sarode; Sachin C Sarode; Barnali Majumdar; Shankargouda Patil
Journal:  Clin Pract       Date:  2018-01-08

8.  Peripheral and Central Giant Cell Lesions in Children: Institutional Experience at Subharti Dental College and Hospital.

Authors:  Preetika Chandna; Nikhil Srivastava; Vishal Bansal; Vijay Wadhwan; Prajesh Dubey
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Oct-Dec

9.  TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw.

Authors:  Carolina Cavalieri Gomes; Tenzin Gayden; Andrea Bajic; Osama F Harraz; Jonathan Pratt; Hamid Nikbakht; Eric Bareke; Marina Gonçalves Diniz; Wagner Henriques Castro; Pascal St-Onge; Daniel Sinnett; HyeRim Han; Barbara Rivera; Leonie G Mikael; Nicolas De Jay; Claudia L Kleinman; Elvis Terci Valera; Angelia V Bassenden; Albert M Berghuis; Jacek Majewski; Mark T Nelson; Ricardo Santiago Gomez; Nada Jabado
Journal:  Nat Commun       Date:  2018-11-01       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.